It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24 ...

Eli Lilly stock has generated fantastic returns for investors over the past five years. The company possesses many lucrative growth opportunities to ensure it remains an excellent buy in the years ...

Eli Lilly is set to keep growing its revenue at a strong pace in the next five years. The company is likely to add important medicines to its lineup. Eli Lilly's shares look attractive right now.

Follow Bloomberg India on WhatsApp for exclusive content and analysis on what billionaires, businesses and markets are doing. Sign up here. Eli Lilly and Co. has begun selling its blockbuster ...

Eli Lilly (LLY) has launched its weight-loss and diabetes drug, Mounjaro (tirzepatide), in India, securing a first-mover advantage in a market with a large obese population. This move positions ...

Eli Lilly (LLY) announces it will invest $27 billion in four new manufacturing sites in the US. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to break down the news.

My DCF analysis suggests that Eli Lilly's stock is 60% undervalued. Defensive healthcare stocks like Eli Lilly are favorable in the current uncertain macroenvironment, driven by tariff concerns ...

Feb. 26 (UPI) --Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in ...

Eli Lilly plans to invest at least $27 billion to build four new pharmaceutical manufacturing sites in the U.S. The drugmaker, which had committed to $23 billion in domestic investments from 2020 ...